Novack David F, President & COO, has demonstrated a clear selling bias in his trading activity involving Dynavax Technologies (DVAX), the only company in which he has reported transactions. Across 44 filings, his total sell value of $4.4 million significantly outweighs his $1.49 million in purchases. The most recent transactions, all occurring in early 2026, reinforce this trend—four sales with no corresponding buys. Notably, on January 15, 2026, Novack executed a series of transactions, including a $1.78 million sale alongside smaller dispositions totaling $1.12 million. This followed a December 24, 2025, sale of $464,700 paired with a $739,885 acquisition, one of the few instances where buying activity appeared. Earlier in 2025, his trades were similarly weighted toward divestment, including a $190,391 sale in March. While the filings include multiple transactions with no reported value—likely representing non-monetary events like option exercises or grants—the monetary trades reveal a consistent pattern of reducing his DVAX position, particularly in the most recent months. The absence of any disclosed purchases since late 2025 suggests a shift toward outright disposition rather than rebalancing. All activity remains confined to Dynavax, indicating concentrated exposure to the biopharmaceutical firm prior to these sales.
AI-assisted summary